Hemorrhagic cystitis (HC) is a known complication of allogenic BMT. We report a case of a 28-year-old female with CML in chronic phase, which was treated with a matched unrelated donor (MUD) transplant, complicated by hemorrhagic cystitis on day +42 after the transplant. Adenovirus was isolated from the urine and she was treated with ribavirin, 1 g twice a day for 8 days. We report the use of Amicar (E-aminocaproic acid), 2.5 g solution as bladder instillation to treat the intractable hematuria.
A 28-year-old Hispanic female with a past medical history of non-insulin dependent diabetes mellitus since 1995 was diagnosed with CML, after her WBC count was found to be 61 ϫ 10 9 /l during a routine examination. The diagnosis was confirmed by the presence of Ph+ cells. She was treated with interferon and hydroxyurea and subsequently underwent a matched unrelated donor transplant. Conditioning included 1200 cGy of total body irradiation (TBI) in fractions of 200 twice a day for 3 days, cyclophosphamide 60 mg/kg/day for 2 days and antithymocyte globulin (ATG; Pharmacia and Upjohn, Indiana, USA) 15 mg/kg/day for 2 days. The patient engrafted on day +16. She suffered neutropenic fever treated with antibiotics and was discharged from the hospital on day +18.
She was readmitted on day +35 with acute grade IV GVHD of the skin. High-dose steroids were added to her immunosuppressive regimen of FK506 (Prograf, Fujisawa, IL, USA) and mycophenolate (Roche, NJ, USA). Three days after admission she experienced frank hematuria. Urine cultures were positive for adenovirus at day +45 and no bacterial pathogens were isolated. Continuous bladder irrigation was initiated and her platelet count was maintained above 50 ϫ 10 9 /l. Ribavarin (Schering Corp, NJ, USA) at a dose of 1 g twice a day was given for 8 days. Despite subsequent negative urine cultures for adenovirus she had persistent, frank hematuria. She then commenced intravesicular Amicar (Immunex, CA, USA) as a 2.5% solution, ie 2.5 g of Amicar in 100 cc of 0.9 normal saline for 1 h three times a day for 3 consecutive days, with complete resolution of the hematuria.
Discussion
Hemorrhagic cystitis is one of the most difficult complications post-allogeneic hematopoietic cell transplant. It may be secondary to infection, pretransplant chemotherapy or radiation therapy. Vidarabine has been reported to be effective for adenovirus-associated HC, but there is no known effective therapy for HC occurring secondary to cyclophosphamide or radiation. The use of continuous bladder irrigation with 0.9 normal saline to prevent clot obstruction combined with transfusion support with blood products is widely accepted.
A review of the literature demonstrates several different strategies used to treat intractable HC. Antivirals such as ribavirin and ganciclovir have been used with variable results, 1,2 for virally induced HC. Other investigators have used prostaglandin F2 alpha, 3 prostaglandin E2, 4 prostaglandin E1, 5 with results varying from complete to partial resolution of hematuria associated with pretransplant chemotherapy or radiation. Alum bladder irrigation has also been reported 6 and the resultant aluminum toxicity has been described. 7 Intravesical instillation of Maalox as a mucous lining protectant has been reported, as has formalin, both being used to stop the intractable hematuria secondary to chemotherapy and radiation, 8, 9 although with considerable patient morbidity. Hyperbaric oxygen has been used with variable results. 10 All of the above interventions would indicate that there is no definite therapy for HC.
The use of Amicar as a local instillation in the bladder is safe and has no side effects. It may act as a local hemostat by stabilizing the clotting process through its antifibrinolytic action much as it does when used locally after tooth extraction. In cyclophosphamide and radiationinduced HC, the local effects of Amicar may not be long lasting and repetitive therapy might be required until spontaneous resolution of hematuria occurs. Further studies are needed to determine the dose, timing, safety and efficacy of Amicar use for patients with intractable hemorrhagic cystitis.
